Type I interferon signature in systemic lupus erythematosus.
Type I interferons (IFN) are primarily regarded as an inhibitor of viral replication. However, type I IFN, mainly IFNalpha, plays a major role in activation of both the innate and adaptive immune systems. Systemic lupus erythematosus (SLE) is a chronic, multi-systemic, inflammatory autoimmune disease with undefined etiology. SLE is characterized by dysregulation of both the innate and the adaptive immune systems. An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE. We review here the role of IFNalpha in the pathogenesis and course of SLE and the possible role of IFNalpha inhibition as a novel treatment for lupus patients.
Shira
S
Bezalel
Keren Mahlab
KM
Guri
Daniel
D
Elbirt
Ilan
I
Asher
Zev Moshe
ZM
Sthoeger
D056704:Adaptive Immunity; D000818:Animals; D005786:Gene Expression Regulation; D006801:Humans; D007113:Immunity, Innate; D007370:Interferon Type I / Q000037:antagonists & inhibitors / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000503:physiopathology
D007370:Interferon Type I